|
MarketVIEW: Chlamydia trachomatis vaccinesPublished by: VacZine Analytics Published: Oct. 1, 2008 - 34 Pages Table of Contents
AbstractAfter the global success of new HPV vaccines focused on sexually transmitted infections, vaccine manufacturers are considering other high-burden infections in the adolescent group, especially Chlamydia trachomatis (CT). CT is a major cause of serious reproductive complications in the female with outcomes such as pelvic inflammatory disease (PID) and ectopic pregnancies. Although diagnosed infections with Chlamydia trachomatis are curable with antibiotic therapy the vast majority infections are “silent” and unrecognized. Even after treatment re-infection rates of CT remain high with little chance of eradication within the population.This MarketVIEW product is a comprehensive Excel-based model forecasting the potential commercial value of a prophylatic Chlamydia vaccine across the seven major markets. The model contains value ($ m) and volume (mio doses) with predictions of launch timeframe, pricing and penetration. Using Gardasil adoption as a case study, the impact of country National Immunization Programs (NIPs) including “catch-up” campaigns are also included. The model tabulates all included assumptions and is easily adjusted with client modifications. Pleasr Note: This is delivered as an Excel file. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||